1D6 is a monoclonal antibody (mAb) which recognizes human CD81. It was identified by its ability to induce aggregation of a human lymphoma B cell line. This mAb is capable of inducing an antiproliferative effect in B cells
Stanford researchers have developed multivalent SIRP-alpha fusion polypeptides that selectively block the CD47–SIRP-alpha immune checkpoint with enhanced potency, enabling next-generation immunotherapies that promote immune clearance of cancer and diseased cells while minimizi
Researchers at Stanford Genome Technology Center have patented a highly sensitive and specific straightforward circular Proximity Ligation Assay (c-PLA) method to reduce background and improve quantitative detection of protein biomarkers through conversion into unique DNA sequ
Researchers at Stanford have developed fusion proteins, containing ACE2 domain linked to a fragment of non-neutralizing anti-SARS-CoV-2 spike protein antibody, with a greater breadth of protection than previously described similar fusion proteins.
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, making it the leading cause of cancer-related deaths globally. Post-surgical recurrence and treatment resistance are the main causes of cancer-related mortality.
Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives.
Stanford scientists have developed the Programmable Antigen-Mediated Cellular Knock-in of T cell (PACK-IT) platform that enables rapid CAR-T cell engineering in hours rather than weeks.
Researchers in Dr. Holden Maecker's lab have developed platinum-labeled probes to expand the analytical capacity of mass cytometry instruments. Currently, analytical capacity is limited by the ability to label specific probes with appropriate metal ions.
Engineered cytotoxic T cells are a promising class of cell therapies. These living drugs are capable of selectively killing blood cancers, such as acute myeloid leukemia (AML), and delaying its progression.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.